PMID- 29191597
OWN - NLM
STAT- MEDLINE
DCOM- 20180705
LR  - 20220410
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 112
DP  - 2017 Oct
TI  - Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic 
      review and meta-analysis.
PG  - 25-34
LID - S0169-5002(17)30402-6 [pii]
LID - 10.1016/j.lungcan.2017.07.023 [doi]
AB  - INTRODUCTION: Cancer anorexia-cachexia syndrome (CACS) is characterized by 
      involuntary weight loss. CACS is commonly observed in advanced non-small-cell 
      lung cancer (NSCLC), and it leads to a poor quality of life (QOL). No effective 
      standard treatment exists for this condition. However, anamorelin has reportedly 
      caused improvement in patients with several cancers. MATERIALS AND METHODS: We 
      conducted a quantitative meta-analysis to explore the efficacy of anamorelin for 
      treating CACS in patients with NSCLC. We systematically searched CENTRAL, 
      MEDLINE, EMBASE, CINAHL, and OvidSP. We pooled the data and calculated and 
      compared total body weight (TBW), lean body mass (LBM), overall survival (OS), 
      hand grip strength (HGS), QOL, and adverse events (AEs) between patients treated 
      with anamorelin (anamorelin group) and those not (placebo group). RESULT: Six 
      randomized controlled trials included 1641 patients with NSCLC. Both TBW and LBM 
      were significantly increased in the anamorelin group compared to the placebo 
      group (mean differences [MD] 1.78, 95%CI: 1.28-2.28, p<0.00001; MD 1.10, 95%CI: 
      0.35-1.85, p=0.004, respectively). The groups showed no difference in OS or HGS 
      (hazard ratio 0.99, 95%CI: 0.85-1.14, p=0.84; MD 0.52, 95% CI: -0.09-1.13, 
      p=0.09, respectively). Anamorelin significantly improved the QOL (standardized MD 
      0.19, 95%CI: 0.08-0.30, p=0.0006). The frequency of any AEs and grade 3 or 4 AEs 
      were not significantly different between groups (risk ratio[RR] 1.03, 95%CI: 
      0.95-1.10, p=0.49; RR 0.86, 95%CI: 0.48-1.54, p=0.62). CONCLUSION: This analysis 
      demonstrated that anamorelin represents a promising treatment option for CACS in 
      patients with advanced NSCLC.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Nishie, Kenichi
AU  - Nishie K
AD  - The First Department of Internal Medicine, Shinshu University School of Medicine, 
      Japan; Department of Respiratory Medicine, Iida Municipal Hospital, Japan. 
      Electronic address: kennishie@imh.jp.
FAU - Yamamoto, Shuhei
AU  - Yamamoto S
AD  - Department of Rehabilitation, Shinshu University Hospital, Japan.
FAU - Nagata, Chie
AU  - Nagata C
AD  - Department of Education for Clinical Research, National Center for Child Health 
      and Development, Japan.
FAU - Koizumi, Tomonobu
AU  - Koizumi T
AD  - Department of Comprehensive Cancer Therapy, Shinshu University School of 
      Medicine, Japan.
FAU - Hanaoka, Masayuki
AU  - Hanaoka M
AD  - The First Department of Internal Medicine, Shinshu University School of Medicine, 
      Japan.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20170727
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Hydrazines)
RN  - 0 (Oligopeptides)
RN  - DD5RBA1NKF (anamorelin)
SB  - IM
MH  - Age Factors
MH  - Body Weight
MH  - Cachexia/*drug therapy/*etiology
MH  - Carcinoma, Non-Small-Cell Lung/*complications/diagnosis
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Hydrazines/administration & dosage/adverse effects/*therapeutic use
MH  - Lung Neoplasms/*complications/diagnosis
MH  - Odds Ratio
MH  - Oligopeptides/administration & dosage/adverse effects/*therapeutic use
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Sex Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Anamorelin
OT  - Cachexia
OT  - Non-small-cell lung cancer
OT  - Weight loss
EDAT- 2017/12/02 06:00
MHDA- 2018/07/06 06:00
CRDT- 2017/12/02 06:00
PHST- 2017/04/20 00:00 [received]
PHST- 2017/07/14 00:00 [revised]
PHST- 2017/07/18 00:00 [accepted]
PHST- 2017/12/02 06:00 [entrez]
PHST- 2017/12/02 06:00 [pubmed]
PHST- 2018/07/06 06:00 [medline]
AID - S0169-5002(17)30402-6 [pii]
AID - 10.1016/j.lungcan.2017.07.023 [doi]
PST - ppublish
SO  - Lung Cancer. 2017 Oct;112:25-34. doi: 10.1016/j.lungcan.2017.07.023. Epub 2017 
      Jul 27.